Scarica l'app Stockscreener
117.36
4.89%
5.47
Pre-mercato:
116.51
-0.85
-0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$111.89
Aprire:
$113.01
Volume 24 ore:
104.48K
Relative Volume:
0.89
Capitalizzazione di mercato:
$2.22B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
46.76
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
+8.12%
1M Prestazione:
+2.37%
6M Prestazione:
+17.64%
1 anno Prestazione:
+61.83%
Intervallo 1D:
$112.53
$117.53
Intervallo di 1 settimana:
$107.99
$117.53
Portata 52W:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
117.36 | 2.22B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Burney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
LGND (Ligand Pharmaceuticals) Debt-to-EBITDA : 0.54 (As of Sep. 2024) - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Don't Ignore The Insider Selling In Ligand Pharmaceuticals - Simply Wall St
Principal Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Is Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
Jane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Jane Street Group LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Octavio Espinoza Executes Sell Order: Offloads $244K In Ligand Pharmaceuticals Stock - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year - Yahoo Finance
MML Investors Services LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $244,850 in stock By Investing.com - Investing.com Canada
Benchmark maintains Buy on Ligand Pharma stock citing consistent financial performance - Investing.com Canada
Geode Capital Management LLC Acquires 22,495 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Raised by Geode Capital Management LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Receives “Buy” Rating from Benchmark - Defense World
Benchmark Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Franklin Resources Inc. Has $9.79 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Barclays PLC Has $4.35 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Stifel Financial Corp Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by HighTower Advisors LLC - Defense World
Wellington Management Group LLP Decreases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Issues Optimistic Estimate for LGND Earnings - Defense World
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
BNP Paribas Financial Markets Sells 1,586 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals' SWOT analysis: royalty aggregator stock poised for growth - Investing.com
What is HC Wainwright's Estimate for LGND FY2025 Earnings? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,031 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
The Manufacturers Life Insurance Company Sells 167 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand price target raised to $151 from $135 at Oppenheimer - Yahoo Finance
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):